Amgen’s Colorectal Cancer Program Proceeding Despite Vectibix PACCE Failure
Company halts the Phase IIIb dual biologics study after an interim analysis showed greater benefit in the control arm and increased toxicity in the arm including Vectibix.
Company halts the Phase IIIb dual biologics study after an interim analysis showed greater benefit in the control arm and increased toxicity in the arm including Vectibix.